Inhibition of the mitochondrial Hsp90 chaperone network: A novel, efficient treatment strategy for cancer?

Cancer Letters

Volumn 333, Issue 2, 2013, Pages 133-146

  Siegelin, Markus D ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Apoptosis; Gamitrinibs; Hsp90; Mitochondrial Hsp90 chaperone network; Preclinical therapy; Shepherdin

Indexed keywords

ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; CHAPERONE; CYCLOPHILIN D; GAMITRINIB; GAMITRINIB DERIVATIVE; GAMITRINIB G4; GAMITRINIB TPP; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOCHONDRIAL PROTEIN; PEPTIDOMIMETIC AGENT; SHEPHERDIN; TANESPIMYCIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROTECTION; CELLULAR STRESS RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENDOPLASMIC RETICULUM; ENERGY YIELD; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FEASIBILITY STUDY; GLIOBLASTOMA; HUMAN; LOW DRUG DOSE; LUNG ADENOCARCINOMA; MESOTHELIOMA; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ANIMALIA;

EID: 84876740528     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.01.045     Document Type: Review

References (110)

1. Schein P.S., Scheffler B. Barriers to efficient development of cancer therapeutics. Clin. Cancer Res. 2006, 12:3243-3248.
2. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The, WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114(2007):97-109.
3. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England J. Med. 2005, 352:987-996.
4. Zhou J., Atsina K.B., Himes B.T., Strohbehn G.W., Saltzman W.M. Novel delivery strategies for glioblastoma. Cancer J. 2012, 18:89-99.
5. Giese A., Bjerkvig R., Berens M.E., Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol: Off. J. Am. Soc. Clin. Oncol. 2003, 21:1624-1636.
6. Bonavia R., Inda M.M., Cavenee W.K., Furnari F.B. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res. 2011, 71:4055-4060.
7. Asuthkar S., Rao J.S., Gondi C.S. Drugs in preclinical and early-stage clinical development for pancreatic cancer. Expert Opin. Inv. Drugs 2012, 21:143-152.
8. Wong K.K. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors. Lung Cancer 2008, 60(Suppl 2):S10-18.
9. Selznick L.A., Shamji M.F., Fecci P., Gromeier M., Friedman A.H., Sampson J. Molecular strategies for the treatment of malignant glioma-genes, viruses, and vaccines. Neurosurg. Rev. 2008, 31:141-155. (Discussion 155).
10. Young K., Minchom A., Larkin J. BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation. Future Oncol 2012, 8:499-507.
11. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., Hogg D., Lorigan P., Lebbe C., Jouary T., Schadendorf D., Ribas A., O'Day S.J., Sosman J.A., Kirkwood J.M., Eggermont A.M., Dreno B., Nolop K., Li J., Nelson B., Hou J., Lee R.J., Flaherty K.T., McArthur G.A. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England J. Med. 2011, 364:2507-2516.
12. Capper D., Preusser M., Habel A., Sahm F., Ackermann U., Schindler G., Pusch S., Mechtersheimer G., Zentgraf H., von Deimling A. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011, 122:11-19.
13. Preusser M., Capper D., Berghoff A.S., Horvat R., Wrba F., Schindl M., Schoppmann S.F., von Deimling A., Birner P. Expression of BRAF V600E Mutant Protein in Epithelial Ovarian Tumors 2012, Applied Immunohistochemistry & Molecular Morphology: AIMM/Official Publication of the Society for Applied Immunohistochemistry.
14. Haroche J., Charlotte F., Arnaud L., von Deimling A., Helias-Rodzewicz Z., Hervier B., Cohen-Aubart F., Launay D., Lesot A., Mokhtari K., Canioni D., Galmiche L., Rose C., Schmalzing M., Croockewit S., Kambouchner M., Copin M.C., Fraitag S., Sahm F., Brousse N., Amoura Z., Donadieu J., Emile J.F. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012, 120:2700-2703.
15. Sahm F., Capper D., Preusser M., Meyer J., Stenzinger A., Lasitschka F., Berghoff A.S., Habel A., Schneider M., Kulozik A., Anagnostopoulos I., Mullauer L., Mechtersheimer G., von Deimling A. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood 2012, 120:e28-e34.
16. Kang B.H., Altieri D.C. Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones. Oncogene 2009, 28:3681-3688.
17. Trepel J., Mollapour M., Giaccone G., Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 2010, 10:537-549.
18. Oliver L., Olivier C., Marhuenda F.B., Campone M., Vallette F.M. Hypoxia and the malignant glioma microenvironment: regulation and implications for therapy. Curr. Molec. Pharmacol. 2009, 2:263-284.
19. Powers M.V., Jones K., Barillari C., Westwood I., van Montfort R.L., Workman P. Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone. Cell Cycle 2010, 9:1542-1550.
20. Dai C., Whitesell L., Rogers A.B., Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007, 130:1005-1018.
21. Mosser D.D., Caron A.W., Bourget L., Meriin A.B., Sherman M.Y., Morimoto R.I., Massie B. The chaperone function of hsp70 is required for protection against stress-induced apoptosis. Mol. Cell. Biol. 2000, 20:7146-7159.
22. Mosser D.D., Morimoto R.I. Molecular chaperones and the stress of oncogenesis. Oncogene 2004, 23:2907-2918.
23. Sheng Z., Li L., Zhu L.J., Smith T.W., Demers A., Ross A.H., Moser R.P., Green M.R. A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nat. Med. 2010, 16:671-677.
24. Sheng Z., Evans S.K., Green M.R. An activating transcription factor 5-mediated survival pathway as a target for cancer therapy. Oncotarget 2010, 1:457-460.
25. Sheng Z., Ma L., Sun J.E., Zhu L.J., Green M.R. BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription. Blood 2011, 118:2840-2848.
26. Li G., Xu Y., Guan D., Liu Z., Liu D.X. HSP70 protein promotes survival of C6 and U87 glioma cells by inhibition of ATF5 degradation. J. Biol. Chem. 2011, 286:20251-20259.
27. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., Burrows F.J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425:407-410.
28. Chen Z., Sasaki T., Tan X., Carretero J., Shimamura T., Li D., Xu C., Wang Y., Adelmant G.O., Capelletti M., Lee H.J., Rodig S.J., Borgman C., Park S.I., Kim H.R., Padera R., Marto J.A., Gray N.S., Kung A.L., Shapiro G.I., Janne P.A., Wong K.K. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res. 2010, 70:9827-9836.
29. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2009, 15:9-14.
30. Kang B.H., Plescia J., Song H.Y., Meli M., Colombo G., Beebe K., Scroggins B., Neckers L., Altieri D.C. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J. Clin. Inv. 2009, 119:454-464.
31. Goloudina A.R., Demidov O.N., Garrido C. Inhibition of HSP70: a challenging anti-cancer strategy. Cancer Lett. 2012, 325:117-124.
32. Powers M.V., Clarke P.A., Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008, 14:250-262.
33. Kang B.H., Plescia J., Dohi T., Rosa J., Doxsey S.J., Altieri D.C. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 2007, 131:257-270.
34. Altieri D.C., Stein G.S., Lian J.B., Languino L.R. TRAP-1, the mitochondrial Hsp90. Biochim. Biophys. Acta 1823, 2012:767-773.
35. Masuda Y., Shima G., Aiuchi T., Horie M., Hori K., Nakajo S., Kajimoto S., Shibayama-Imazu T., Nakaya K. Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin. J. Biol. Chem. 2004, 279:42503-42515.
36. Im C.N., Lee J.S., Zheng Y., Seo J.S. Iron chelation study in a normal human hepatocyte cell line suggests that tumor necrosis factor receptor-associated protein 1 (TRAP1) regulates production of reactive oxygen species. J. Cell. Biochem. 2007, 100:474-486.
37. Siegelin M.D., Plescia J., Raskett C.M., Gilbert C.A., Ross A.H., Altieri D.C. Global targeting of subcellular heat shock protein-90 networks for therapy of glioblastoma. Mol. Cancer Ther. 2010, 9:1638-1646.
38. Leav I., Plescia J., Goel H.L., Li J., Jiang Z., Cohen R.J., Languino L.R., Altieri D.C. Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am J Pathol 2010, 176:393-401.
39. Costantino E., Maddalena F., Calise S., Piscazzi A., Tirino V., Fersini A., Ambrosi A., Neri V., Esposito F., Landriscina M. TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells. Cancer Lett. 2009, 279:39-46.
40. Ghosh J.C., Siegelin M.D., Dohi T., Altieri D.C. Heat shock protein 60 regulation of the mitochondrial permeability transition pore in tumor cells. Cancer Res. 2010, 70:8988-8993.
41. Plescia J., Salz W., Xia F., Pennati M., Zaffaroni N., Daidone M.G., Meli M., Dohi T., Fortugno P., Nefedova Y., Gabrilovich D.I., Colombo G., Altieri D.C. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005, 7:457-468.
42. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997, 3:917-921.
43. P. Fortugno, E. Beltrami, J. Plescia, J. Fontana, D. Pradhan, P.C. Marchisio, W.C. Sessa, D.C. Altieri, Regulation of survivin function by Hsp90, in: Proceedings of the National Academy of Sciences of the United States of America, vol. 100, 2003, p. 13791-13796.
44. Neckers L., Kern A., Tsutsumi S. Hsp90 inhibitors disrupt mitochondrial homeostasis in cancer cells. Chem. Biol. 2007, 14:1204-1206.
45. Dohi T., Beltrami E., Wall N.R., Plescia J., Altieri D.C. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J. Clin. Inv. 2004, 114:1117-1127.
46. Gyurkocza B., Plescia J., Raskett C.M., Garlick D.S., Lowry P.A., Carter B.Z., Andreeff M., Meli M., Colombo G., Altieri D.C. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J. Natl. Cancer Inst. 2006, 98:1068-1077.
47. Sugita T., Yoshikawa T., Mukai Y., Yamanada N., Imai S., Nagano K., Yoshida Y., Shibata H., Yoshioka Y., Nakagawa S., Kamada H., Tsunoda S., Tsutsumi Y. Improved cytosolic translocation and tumor-killing activity of Tat-shepherdin conjugates mediated by co-treatment with Tat-fused endosome-disruptive HA2 peptide. Biochem. Biophys. Res. Commun. 2007, 363:1027-1032.
48. Siegelin M.D., Plescia J., Raskett C.M., Gilbert C.A., Ross A.H., Altieri D.C. Global targeting of subcellular heat shock protein-90 networks for therapy of glioblastoma. Mol. Cancer Therap. 2010, 9:1638-1646.
49. Meli M., Pennati M., Curto M., Daidone M.G., Plescia J., Toba S., Altieri D.C., Zaffaroni N., Colombo G. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead. J. Med. Chem. 2006, 49:7721-7730.
50. Armstrong J.S. Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Brit. J. Pharmacol. 2007, 151:1154-1165.
51. Fernandez-Carneado J., Van Gool M., Martos V., Castel S., Prados P., de Mendoza J., Giralt E. Highly efficient, nonpeptidic oligoguanidinium vectors that selectively internalize into mitochondria. J. Am. Chem. Soc. 2005, 127:869-874.
52. Letai A.G. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat. Rev. Cancer 2008, 8:121-132.
53. Kang B.H., Siegelin M.D., Plescia J., Raskett C.M., Garlick D.S., Dohi T., Lian J.B., Stein G.S., Languino L.R., Altieri D.C. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2010, 16:4779-4788.
54. Siegelin M.D., Dohi T., Raskett C.M., Orlowski G.M., Powers C.M., Gilbert C.A., Ross A.H., Plescia J., Altieri D.C. Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J. Clin. Inv. 2011, 121:1349-1360.
55. Kang B.H., Tavecchio M., Goel H.L., Hsieh C.C., Garlick D.S., Raskett C.M., Lian J.B., Stein G.S., Languino L.R., Altieri D.C. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease. Brit. J Cancer 2011, 104:629-634.
56. Mathew R., Karp C.M., Beaudoin B., Vuong N., Chen G., Chen H.Y., Bray K., Reddy A., Bhanot G., Gelinas C., Dipaola R.S., Karantza-Wadsworth V., White E. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009, 137:1062-1075.
57. Moisoi N., Klupsch K., Fedele V., East P., Sharma S., Renton A., Plun-Favreau H., Edwards R.E., Teismann P., Esposti M.D., Morrison A.D., Wood N.W., Downward J., Martins L.M. Mitochondrial dysfunction triggered by loss of HtrA2 results in the activation of a brain-specific transcriptional stress response. Cell Death Differ. 2009, 16:449-464.
58. Zhao Q., Wang J., Levichkin I.V., Stasinopoulos S., Ryan M.T., Hoogenraad N.J. A mitochondrial specific stress response in mammalian cells. EMBO J. 2002, 21:4411-4419.
59. Cao S.S., Kaufman R.J. Unfolded protein response. Curr. Biol. CB 2012, 22:R622-626.
60. Barone M.V., Crozat A., Tabaee A., Philipson L., Ron D. CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrest. Genes Dev. 1994, 8:453-464.
61. Zinszner H., Kuroda M., Wang X., Batchvarova N., Lightfoot R.T., Remotti H., Stevens J.L., Ron D. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev. 1998, 12:982-995.
62. Siegelin M.D. Utilization of the cellular stress response to sensitize cancer cells to TRAIL-mediated apoptosis. Expert Opin. Ther. Targets 2012, 16:801-817.
63. McCullough K.D., Martindale J.L., Klotz L.O., Aw T.Y., Holbrook N.J. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol. Cell. Biol. 2001, 21:1249-1259.
64. Rambold A.S., Lippincott-Schwartz J. Mechanisms of mitochondria and autophagy crosstalk. Cell Cycle 2011, 10:4032-4038.
65. Narendra D., Tanaka A., Suen D.F., Youle R.J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 2008, 183:795-803.
66. Geisler S., Holmstrom K.M., Skujat D., Fiesel F.C., Rothfuss O.C., Kahle P.J., Springer W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 2010, 12:119-131.
67. Matsuda N., Sato S., Shiba K., Okatsu K., Saisho K., Gautier C.A., Sou Y.S., Saiki S., Kawajiri S., Sato F., Kimura M., Komatsu M., Hattori N., Tanaka K. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J. Cell Bio. 2010, 189:211-221.
68. Walden H., Martinez-Torres R.J. Regulation of Parkin E3 ubiquitin ligase activity. Cell. Mol. Life Sci.: CMLS 2012, 69:3053-3067.
69. Martin S.A., Hewish M., Sims D., Lord C.J., Ashworth A. Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. Cancer Res. 2011, 71:1836-1848.
70. Pridgeon J.W., Olzmann J.A., Chin L.S., Li L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol. 2007, 5:e172.
71. Kabeya Y., Mizushima N., Ueno T., Yamamoto A., Kirisako T., Noda T., Kominami E., Ohsumi Y., Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000, 19:5720-5728.
72. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C., Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. New England J. Med. 2005, 352:997-1003.
73. Kanzawa T., Germano I.M., Komata T., Ito H., Kondo Y., Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 2004, 11:448-457.
74. Chae Y.C., Caino M.C., Lisanti S., Ghosh J.C., Dohi T., Danial N.N., Villanueva J., Ferrero S., Vaira V., Santambrogio L., Bosari S., Languino L.R., Herlyn M., Altieri D.C. Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s. Cancer Cell 2012, 22:331-344.
75. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
76. Mathupala S.P., Ko Y.H., Pedersen P.L. The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim. Biophys. Acta 2010, 1797:1225-1230.
77. Ward P.S., Thompson C.B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21:297-308.
78. Pedersen P.L., Mathupala S., Rempel A., Geschwind J.F., Ko Y.H. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim. Biophys. Acta 2002, 1555:14-20.
79. Machida K., Ohta Y., Osada H. Suppression of apoptosis by cyclophilin D via stabilization of hexokinase II mitochondrial binding in cancer cells. J. Biol. Chem. 2006, 281:14314-14320.
80. Pastorino J.G., Shulga N., Hoek J.B. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J. Biol. Chem. 2002, 277:7610-7618.
81. Gottlob K., Majewski N., Kennedy S., Kandel E., Robey R.B., Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 2001, 15:1406-1418.
82. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
83. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
84. Zaytseva Y.Y., Valentino J.D., Gulhati P., Evers B.M. MTOR inhibitors in cancer therapy. Cancer Lett. 2012, 319:1-7.
85. Shaw R.J., Bardeesy N., Manning B.D., Lopez L., Kosmatka M., DePinho R.A., Cantley L.C. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004, 6:91-99.
86. Ollila S., Makela T.P. The tumor suppressor kinase LKB1: lessons from mouse models. J. Mol. Cell. Biol. 2011, 3:330-340.
87. Wingo S.N., Gallardo T.D., Akbay E.A., Liang M.C., Contreras C.M., Boren T., Shimamura T., Miller D.S., Sharpless N.E., Bardeesy N., Kwiatkowski D.J., Schorge J.O., Wong K.K., Castrillon D.H. Somatic LKB1 mutations promote cervical cancer progression. PloS One 2009, 4:e5137.
88. Wiederrecht G.J., Sabers C.J., Brunn G.J., Martin M.M., Dumont F.J., Abraham R.T. Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. Prog. Cell Cycle Res. 1995, 1:53-71.
89. Schieke S.M., Phillips D., McCoy J.P., Aponte A.M., Shen R.F., Balaban R.S., Finkel T. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J. Biol. Chem. 2006, 281:27643-27652.
90. Kourelis T.V., Siegel R.D. Metformin and cancer: new applications for an old drug. Med. Oncol. 2012, 29:1314-1327.
91. Dowling R.J., Zakikhani M., Fantus I.G., Pollak M., Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007, 67:10804-10812.
92. Jung C.H., Ro S.H., Cao J., Otto N.M., Kim D.H. MTOR regulation of autophagy. FEBS Lett. 2010, 584:1287-1295.
93. Sudarsanam S., Johnson D.E. Functional consequences of mTOR inhibition. Curr. Opin. Drug Discov. Dev. 2010, 13:31-40.
94. Amoroso M.R., Matassa D.S., Laudiero G., Egorova A.V., Polishchuk R.S., Maddalena F., Piscazzi A., Paladino S., Sarnataro D., Garbi C., Landriscina M., Esposito F. TRAP1 and the proteasome regulatory particle TBP7/Rpt3 interact in the endoplasmic reticulum and control cellular ubiquitination of specific mitochondrial proteins. Cell Death Differ. 2012, 19:592-604.
95. Pyrko P., Schonthal A.H., Hofman F.M., Chen T.C., Lee A.S. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res. 2007, 67:9809-9816.
96. Candolfi M., Curtin J.F., Nichols W.S., Muhammad A.G., King G.D., Pluhar G.E., McNiel E.A., Ohlfest J.R., Freese A.B., Moore P.F., Lerner J., Lowenstein P.R., Castro M.G. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J. Neuro-Oncol. 2007, 85:133-148.
97. Kaplan-Lefko P.J., Chen T.M., Ittmann M.M., Barrios R.J., Ayala G.E., Huss W.J., Maddison L.A., Foster B.A., Greenberg N.M. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003, 55:219-237.
98. Solit D.B., Zheng F.F., Drobnjak M., Munster P.N., Higgins B., Verbel D., Heller G., Tong W., Cordon-Cardo C., Agus D.B., Scher H.I., Rosen N. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2002, 8:986-993.
99. Dimberg L.Y., Anderson C.K., Camidge R., Behbakht K., Thorburn A., Ford H.L. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 2012.
100. Pollack I.F., Erff M., Ashkenazi A. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2001, 7:1362-1369.
101. Jin H., Yang R., Fong S., Totpal K., Lawrence D., Zheng Z., Ross J., Koeppen H., Schwall R., Ashkenazi A. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res. 2004, 64:4900-4905.
102. Soria J.C., Smit E., Khayat D., Besse B., Yang X., Hsu C.P., Reese D., Wiezorek J., Blackhall F. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2010, 28:1527-1533.
103. Thorburn A., Behbakht K., Ford H. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist. Updates: Rev. Commentaries Antimicrob. Anticancer Chemoth. 2008, 11:17-24.
104. Baldwin A.S. Regulation of cell death and autophagy by IKK and NF-kappaB: critical mechanisms in immune function and cancer. Immunolog. Rev. 2012, 246:327-345.
105. Fulda S. Targeting c-FLICE-like inhibitory protein (CFLAR) in cancer. Expert Opin. Ther. Targets 2012.
106. Xiao C., Yang B.F., Asadi N., Beguinot F., Hao C. Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J. Biol. Chem. 2002, 277:25020-25025.
107. Panner A., James C.D., Berger M.S., Pieper R.O. MTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol. Cell. Biol. 2005, 25:8809-8823.
108. Nimmanapalli R., O'Bryan E., Kuhn D., Yamaguchi H., Wang H.G., Bhalla K.N. Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-XL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases. Blood 2003, 102:269-275.
109. Williams C.R., Tabios R., Linehan W.M., Neckers L. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. J. Urol. 2007, 178:1528-1532.
110. Sawai A., Chandarlapaty S., Greulich H., Gonen M., Ye Q., Arteaga C.L., Sellers W., Rosen N., Solit D.B. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res. 2008, 68:589-596.